The chemical class of TI-VAMP inhibitors predominantly focuses on indirect strategies to modulate the function of TI-VAMP/VAMP7 by targeting various aspects of vesicular transport and membrane dynamics. These chemicals intervene in different stages of intracellular transport, ranging from vesicle formation to membrane fusion processes. The approach to indirectly inhibit TI-VAMP's function is based on the understanding that disrupting the cellular transport pathways can effectively modulate the protein's role in these processes. Brefeldin A and Golgicide A, for instance, target the Golgi apparatus, a critical station in vesicular transport, thereby impacting the trafficking routes essential for TI-VAMP function. Similarly, compounds like Nocodazole and Vinblastine, which interfere with microtubule dynamics, affect the transport of vesicles along these cytoskeletal structures. This disruption can indirectly affect the role of TI-VAMP in vesicular fusion events.
On the other hand, inhibitors like Dynasore and Pitstop 2 specifically target the endocytic pathway by inhibiting dynamin and clathrin, respectively. These interventions can significantly impact the vesicle formation and trafficking processes, indirectly influencing TI-VAMP's role in these pathways. Additionally, compounds like Cytochalasin D and Latrunculin A disrupt the actin cytoskeleton, further highlighting the broad spectrum of mechanisms that can be employed to indirectly modulate TI-VAMP activity. The development and application of these inhibitors provide valuable tools in cellular and molecular biology to study vesicular transport and membrane dynamics. By understanding how these chemicals affect various components and stages of the cellular transport system, researchers can gain insights into the complex mechanisms regulating vesicle trafficking and fusion, in which TI-VAMP plays a crucial role. While these inhibitors do not directly target TI-VAMP, their effects on the protein's functional environment offer a means to study and potentially modulate its activity in a cellular context.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Disrupts Golgi structure and function, impacting vesicular transport. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Inhibits dynamin, impacting clathrin-mediated endocytosis and vesicle formation. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Disrupts microtubules, affecting vesicular transport processes. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Inhibits actin polymerization, disrupting cytoskeletal dynamics and vesicle movement. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, impacting endosomal trafficking and membrane dynamics. | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $265.00 $815.00 | 36 | |
Disrupts actin filaments, affecting cellular transport and membrane dynamics. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation, affecting protein trafficking and stability. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Specifically targets the Golgi BFA resistance factor 1 (GBF1), disrupting Golgi function. | ||||||
Vinblastine | 865-21-4 | sc-491749 sc-491749A sc-491749B sc-491749C sc-491749D | 10 mg 50 mg 100 mg 500 mg 1 g | $102.00 $235.00 $459.00 $1749.00 $2958.00 | 4 | |
Alkaloid that disrupts microtubules, impacting vesicle transport and cellular trafficking. | ||||||